Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide
April 18, 2023 07:10 ET
|
Arch Biopartners
TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel...